A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients.
Prostate cancer is the most common cancer among men in many countries, including the US and UK. About 1.5 million men are diagnosed worldwide each year.
The new drug has caused excitement as it is a type of treatment called immunotherapy. This approach uses the body’s own immune system to fight disease, and has already proved beneficial for some cancers.
Photo: Bloomberg
However, experts say it has not yet had the same impact on prostate cancer.
Now scientists have reported results from an early stage trial of an immunotherapy drug called VIR-5500, suggesting it could offer hope to men with advanced prostate cancer.
“We believe that such treatments may in the long term lead to cures,” said Johann de Bono of the Institute of Cancer Research and the Royal Marsden NHS foundation trust, who led the work.
VIR-5500was an engineered antibody that brought together the body’s killer T-cells with tumor cells trying to evade them, De Bono said.
This type of drug, called a T-cell engager, allowed the killer cells to wipe out the tumor ones.
The special feature of VIR-5500 was that it was designed to only become activated within the tumor, De Bono added.
This not only minimized side effects — an important consideration as other T-cell engagers have been found to trigger severe inflammatory responses in people with prostate cancer — but allowed the drug to linger in the bloodstream, meaning fewer doses might be needed.
Under the phase one clinical trial, funded by Vir Biotechnology, 58 men with advanced prostate cancer, and who had stopped responding to other treatments, were given VIR-5500.
The researchers found the majority of patients — 88 percent — experienced only very mild side effects.
Then, they looked at the level of prostate-specific antigen (PSA) in the men’s blood — a biomarker whereby higher levels can be a sign of prostate conditions.
De Bono said the trial started at low doses, with the dose increasing in stages.
When the team looked at data for 17 men given the highest dose, they found that for 14 (82 percent) their PSA level fell by at least half after treatment, nine (53 percent) saw their PSA level fall by at least 90 percent, and five (29 percent) experienced a fall of at least 99 percent.
De Bono described the results as unprecedented for a disease previously thought to be “immune-cold,” in other words resistant to immunotherapy.
The team added that, of 11 people given the highest dose and whose tumors were measurable, five showed tumor shrinkage. In one case involving a 63-year-old man whose cancer had spread to his liver, the team found 14 cancerous liver lesions “completely resolved” after six cycles of treatment.
The results, which have not yet been peer-reviewed, were presented at the American Society of Clinical Oncology genitourinary cancers symposium in San Francisco.
Further clinical trials are now being planned, De Bono said.
“We do need more data, but the results are stunning,” he said.
Imperial College London cancer biology professor Charlotte Bevan, who was not involved in the work, said an advance in using immunotherapy for prostate cancer was potentially very exciting, opening up a new class of drug.
However, it was important studies were carried out with people of different ethnicities, as there were disparities in prostate cancer outcomes, she said.
Prostate Cancer UK assistant director of research Simon Grieveson described the early-phase trial as exciting.
“With over 12,000 men dying from prostate cancer each year in the UK, we urgently need new and innovative ways to treat the disease,” he said. “These early results are extremely promising, with a number of men on the study responding positively to the treatment with minimal side effects. I look forward to seeing this now tested in larger trials, with the hope that this treatment will offer men more valuable time with their loved ones.”
MONEY GRAB: People were rushing to collect bills scattered on the ground after the plane transporting money crashed, which an official said hindered rescue efforts A cargo plane carrying money on Friday crashed near Bolivia’s capital, damaging about a dozen vehicles on highway, scattering bills on the ground and leaving at least 15 people dead and others injured, an official said. Bolivian Minister of Defense Marcelo Salinas said the Hercules C-130 plane was transporting newly printed Bolivian currency when it “landed and veered off the runway” at an airport in El Alto, a city adjacent to La Paz, before ending up in a nearby field. Firefighters managed to put out the flames that engulfed the aircraft. Fire chief Pavel Tovar said at least 15 people died, but
LIKE FATHER, LIKE DAUGHTER: By showing Ju-ae’s ability to handle a weapon, the photos ‘suggest she is indeed receiving training as a successor,’ an academic said North Korea on Saturday released a rare image of leader Kim Jong-un’s teenage daughter firing a rifle at a shooting range, adding to speculation that she is being groomed as his successor. Kim’s daughter, Ju-ae, has long been seen as the next in line to rule the secretive, nuclear-armed state, and took part in a string of recent high-profile outings, including last week’s military parade marking the closing stages of North Korea’s key party congress. Pyongyang’s official Korean Central News Agency (KCNA) released a photo of Ju-ae shooting a rifle at an outdoor shooting range, peering through a rifle scope
India and Canada yesterday reached a string of agreements, including on critical mineral cooperation and a “landmark” uranium supply deal for nuclear power, the countries’ leaders said in New Delhi. The pacts, which also covered technology and promoting the use of renewable energy, were announced after Indian Prime Minister Narendra Modi and Canadian Prime Minister Mark Carney hailed a fresh start in the relationship between their nations. “Our ties have seen a new energy, mutual trust and positivity,” Modi said. Carney’s visit is a key step forward in ties that effectively collapsed in 2023 after Ottawa accused New Delhi
Gaza is rapidly running out of its limited fuel supply and stocks of food staples might become tight, officials said, after Israel blocked the entry of fuel and goods into the war-shattered territory, citing fighting with Iran. The Israeli military closed all Gaza border crossings on Saturday after announcing airstrikes on Iran carried out jointly with the US. Israeli authorities late on Monday night said that they would reopen the Kerem Shalom crossing from Israel to Gaza yesterday, for “gradual entry of humanitarian aid” into the strip, without saying how much. Israeli authorities previously said the crossings could not be operated safely during
RSS